Showing results (21-30 of 27) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Modern Rheumatology|August 3, 2022
Safety and efficacy of filgotinib for Japanese patients with RA and inadequate response to MTX: FINCH 1 52-week results and FINCH 4 48-week resultsYoshiya Tanaka, Tsukasa Matsubara, Tatsuya Atsumi, et al.Modern Rheumatology|December 15, 2021
Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1)Yoshiya Tanaka, Tsukasa Matsubara, Tatsuya Atsumi, et al.Annals of the Rheumatic Diseases|January 16, 2021
Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trialRené Westhovens, William F C Rigby, Désirée van der Heijde, et al.Annals of the Rheumatic Diseases|January 28, 2021
Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trialBernard Combe, Alan Kivitz, Yoshiya Tanaka, et al.Science Translational Medicine|May 22, 2015
Targeting phosphatase-dependent proteoglycan switch for rheumatoid arthritis therapyKaren M Doody, Stephanie M Stanford, Cristiano Sacchetti, et al.Annals of the Rheumatic Diseases|February 28, 2019
PTPN14 phosphatase and YAP promote TGFβ signalling in rheumatoid synoviocytesAngel Bottini, Dennis J Wu, Rizi Ai, et al.RMD Open|October 6, 2025
Key considerations for advancing chimeric antigen receptor (CAR) T-cell therapy for systemic lupus erythematosus (SLE): a multi-partner/disciplinary working group perspectiveElena W Y Hsieh, James B Chung, Afsah Amin, et al.Pageof 3